SCHEMBL4448056

SCHEMBL4448056

CCCCCCCCCCc1cc(O)cc(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 1.00
CYP3A4 P08684 2/20 0.95
ESR1 P03372 2/20 0.63
ADRA2A P08913 2/20 0.63
ADORA3 P0DMS8 2/20 0.63
TACR2 P21452 2/20 0.63
SLC6A2 P23975 2/20 0.63
SLC6A4 P31645 2/20 0.63
SLC6A3 Q01959 2/20 0.63
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.63
LMNA P02545 1/20 0.63
SHBG P04278 1/20 0.63
TP53 P04637 1/20 0.63
HSPD1 P10809 1/20 0.63
ADRB3 P13945 1/20 0.63
HTR2C P28335 1/20 0.63
HSPE1 P61604 1/20 0.63
HIF1A Q16665 1/20 0.63
TST Q16762 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11737365 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
Cardol SCHEMBL406402 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL2464812 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL16432840 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1914183 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL16431835 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL17201654 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL2468227 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL2178058 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL70057 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101522738-A Modified alkylresorcinol resins and applications thereof INDSPEC CHEMICAL CORP (US) 2009-09-02 CN claimed
EP-2087022-A1 MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF INDSPEC CHEMICAL CORPORATION (US) 2009-08-12 EP claimed
WO-2008048839-A1 MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF INDSPEC CHEMICAL CORPORATION (US) 2008-04-24 WO claimed
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-11129781-B2 Agent for hair deforming treatment KAO CORPORATION (JP) 2021-09-28 US disclosed
US-11045402-B2 Hair cosmetic composition KAO CORPORATION (JP) 2021-06-29 US disclosed
CN-109897162-B Epoxy resin with release function, cured product and carbon fiber composite material thereof 江苏澳盛复合材料科技有限公司 2021-05-18 CN disclosed
US-10959925-B2 Hair cosmetic composition KAO CORPORATION (JP) 2021-03-30 US disclosed
EP-3228302-B1 HAIR DEFORMATION TREATMENT AGENT KAO CORP (JP) 2020-09-02 EP disclosed
CN-106999382-B Hair deforming agent 花王株式会社 2020-07-10 CN disclosed
CN-106999380-B Hair deforming agent 花王株式会社 2020-05-05 CN disclosed
EP-2087022-A1 MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF INDSPEC CHEMICAL CORPORATION (US) 2009-08-12 EP disclosed
WO-2008048839-A1 MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF INDSPEC CHEMICAL CORPORATION (US) 2008-04-24 WO disclosed
US-20080090967-A1 Modified Alkylresorcinol Resins and Applications Thereof INDSPEC CHEMICAL CORPORATION (US) 2008-04-17 US disclosed
CN-1954805-A Application of resorcin compound for preparing antitumor medicine UNIV ZHONGNAN (CN) 2007-05-02 CN disclosed
US-5859067-A PREPARING BIS(2-HYDROXY-1-NAPHTHYL)DECANE FROM THE CORRESPONDING DIACID; FORMING ACID DICHLORIDE; TREATING WITH 2-NAPHTHOL; REARRANGEMENT; REDUCTION; INHIBITS ACTION OF ADENOSINE TRIPHOSPHATASE ROUFOGALIS BASIL DON (AU) 1999-01-12 US disclosed
US-5741821-A PHENOLIC ENZYME INHIBITORS THE UNIVERSITY OF SYDNEY (AU) 1998-04-21 US disclosed
EP-0703780-A4 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE UNIV SYDNEY (AU) 1998-01-07 EP disclosed
EP-0703780-A1 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THE UNIVERSITY OF SYDNEY (AU) 1996-04-03 EP disclosed
WO-1994028886-A1 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THE UNIVERSITY OF SYDNEY (AU) 1994-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090967-A1 Modified Alkylresorcinol Resins and Applications Thereof OGG1, ERCC1, MACROD2 PTGS2 1708/4885CYP3A4 623/4885ESR1 45/4885
US-11045402-B2 Hair cosmetic composition CUTA, GRHPR, POLR1C PTGS2 1901/4885CYP3A4 1895/4885ESR1 3488/4885
US-10959925-B2 Hair cosmetic composition CUTA, POLR1C, GRHPR PTGS2 2392/4885CYP3A4 1786/4885ESR1 2417/4885
US-11129781-B2 Agent for hair deforming treatment GRHPR, SLC26A4, COL1A1 PTGS2 3041/4885CYP3A4 3291/4885ESR1 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.